Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rafael Rosell

Showing results (101-110 of 565) with videos related to

Pageof 57
Sort By:
Translational Lung Cancer Research|March 26, 2015
Front-line erlotinib in unselected patients with advanced NSCLC and poor performance status - the TOPICAL studyNiki Karachaliou, Jia Wei, Ana Daniela Marques, et al.
Expert Opinion on Biological Therapy|February 15, 2019
Biological therapies in lung cancer treatment: using our immune system as an ally to defeat the malignancyMartyna Filipska, Carlos Pedraz-Valdunciel, Imane Chaib, et al.
Translational Lung Cancer Research|November 6, 2018
Inhibition of MEK, a canonical KRAS pathway effector in <i>KRAS</i> mutant NSCLCRafael Rosell, Niki Karachaliou, Carles Codony-Servat, et al.
Oncology (Williston Park, N.Y.)|January 20, 2005
Pemetrexed in front-line chemotherapy for advanced non-small-cell lung cancerGiorgio V Scagliotti, Silvia Novello, Lucio Crino, et al.
Translational Lung Cancer Research|November 19, 2019
Targeting PKCι-PAK1 in EGFR-mutation positive non-small cell lung cancerMasaoki Ito, Carles Codony-Servat, Niki Karachaliou, et al.
Translational Lung Cancer Research|March 26, 2015
10(th) Congress on Lung Cancer-updates on clinical trials: goalRosario García Campelo, Bartomeu Massuti, Joaquín Mosquera, et al.
Annals of Translational Medicine|October 22, 2015
Predictive factors for immunotherapy in melanomaCristina Teixidó, Maria González-Cao, Niki Karachaliou, et al.
Expert Review of Anticancer Therapy|March 12, 2014
Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyondNiki Karachaliou, Rafael Rosell, Daniela Morales-Espinosa, et al.
Translational Lung Cancer Research|March 26, 2015
Predicting resistance by selection of signaling pathwaysNiki Karachaliou, Rafael Rosell, Miguel Angel Molina, et al.
The Lancet. Respiratory Medicine|September 12, 2024
Plinabulin, a microtubule destabilising agent, in non-small-cell lung cancer: lessons from the DUBLIN-3 trialRafael Rosell, María González-Cao, Miguel Angel Molina-Vila
Pageof 57

Showing results (101-110 of 565) with videos related to

Sort By:
Pageof 57
Translational Lung Cancer Research|March 26, 2015
Front-line erlotinib in unselected patients with advanced NSCLC and poor performance status - the TOPICAL studyNiki Karachaliou, Jia Wei, Ana Daniela Marques, et al.
Expert Opinion on Biological Therapy|February 15, 2019
Biological therapies in lung cancer treatment: using our immune system as an ally to defeat the malignancyMartyna Filipska, Carlos Pedraz-Valdunciel, Imane Chaib, et al.
Translational Lung Cancer Research|November 6, 2018
Inhibition of MEK, a canonical KRAS pathway effector in <i>KRAS</i> mutant NSCLCRafael Rosell, Niki Karachaliou, Carles Codony-Servat, et al.
Oncology (Williston Park, N.Y.)|January 20, 2005
Pemetrexed in front-line chemotherapy for advanced non-small-cell lung cancerGiorgio V Scagliotti, Silvia Novello, Lucio Crino, et al.
Translational Lung Cancer Research|November 19, 2019
Targeting PKCι-PAK1 in EGFR-mutation positive non-small cell lung cancerMasaoki Ito, Carles Codony-Servat, Niki Karachaliou, et al.
Translational Lung Cancer Research|March 26, 2015
10(th) Congress on Lung Cancer-updates on clinical trials: goalRosario García Campelo, Bartomeu Massuti, Joaquín Mosquera, et al.
Annals of Translational Medicine|October 22, 2015
Predictive factors for immunotherapy in melanomaCristina Teixidó, Maria González-Cao, Niki Karachaliou, et al.
Expert Review of Anticancer Therapy|March 12, 2014
Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyondNiki Karachaliou, Rafael Rosell, Daniela Morales-Espinosa, et al.
Translational Lung Cancer Research|March 26, 2015
Predicting resistance by selection of signaling pathwaysNiki Karachaliou, Rafael Rosell, Miguel Angel Molina, et al.
The Lancet. Respiratory Medicine|September 12, 2024
Plinabulin, a microtubule destabilising agent, in non-small-cell lung cancer: lessons from the DUBLIN-3 trialRafael Rosell, María González-Cao, Miguel Angel Molina-Vila
Pageof 57